Abstract
Biomedical research cannot succeed without funding, knowledgeable staff, and appropriate infrastructure. There are however equally important but intangible factors that are rarely considered in planning large multidisciplinary endeavors or evaluating their success. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial required extensive collaborations between individuals from many fields, including clinicians, clinical trialists, and administrators; it also addressed questions across the spectrum of cancer prevention and control. In this manuscript, we examine the experiences and opinions of trial staff regarding the building of successful relationships in PLCO. We summarize, in narrative form, data collected using open-ended questionnaires that were administered to the National Cancer Institute project officers, coordinating center staff, screening center principal investigators, and screening center coordinators in 2015, about 3 years after publication of the final primary trial manuscript. Trust, respect, listening to others, and in-person interaction were frequently mentioned as crucial to building successful relationships.
Keywords: Cancer screening, collaboration, multidisciplinary, PLCO, randomized controlled trials as subject, team science.
Reviews on Recent Clinical Trials
Title:Building Successful Relationships in the PLCO Cancer Screening Trial
Volume: 10 Issue: 3
Author(s): Victoria Jenkins, Susan Yurgalevitch, Lance A. Yokochi, Vicki Shambaugh, Douglas Reding, Philip C. Prorok, Sheryl L. Ogden, Barbara O’Brien, Karen Lappe, Christine C. Johnson, Pamela M. Marcus, Rachel Jaggi, Darlene Higgins, Lisa H. Gren, John K. Gohagan, Timothy R. Church, Jeffery Childs, Saundra S. Buys and Karen G. Broski
Affiliation:
Keywords: Cancer screening, collaboration, multidisciplinary, PLCO, randomized controlled trials as subject, team science.
Abstract: Biomedical research cannot succeed without funding, knowledgeable staff, and appropriate infrastructure. There are however equally important but intangible factors that are rarely considered in planning large multidisciplinary endeavors or evaluating their success. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial required extensive collaborations between individuals from many fields, including clinicians, clinical trialists, and administrators; it also addressed questions across the spectrum of cancer prevention and control. In this manuscript, we examine the experiences and opinions of trial staff regarding the building of successful relationships in PLCO. We summarize, in narrative form, data collected using open-ended questionnaires that were administered to the National Cancer Institute project officers, coordinating center staff, screening center principal investigators, and screening center coordinators in 2015, about 3 years after publication of the final primary trial manuscript. Trust, respect, listening to others, and in-person interaction were frequently mentioned as crucial to building successful relationships.
Export Options
About this article
Cite this article as:
Jenkins Victoria, Yurgalevitch Susan, A. Yokochi Lance, Shambaugh Vicki, Reding Douglas, C. Prorok Philip, L. Ogden Sheryl, O’Brien Barbara, Lappe Karen, C. Johnson Christine, M. Marcus Pamela, Jaggi Rachel, Higgins Darlene, H. Gren Lisa, K. Gohagan John, R. Church Timothy, Childs Jeffery, S. Buys Saundra and G. Broski Karen, Building Successful Relationships in the PLCO Cancer Screening Trial, Reviews on Recent Clinical Trials 2015; 10 (3) . https://dx.doi.org/10.2174/1574887110666150731131743
DOI https://dx.doi.org/10.2174/1574887110666150731131743 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanocosmetics: Past, Present and Future Trends
Recent Patents on Nanomedicine The Cardiac Antihypertrophic Effects of Cyclic GMP-Generating Agents: An Experimental Framework for Novel Treatments of Left Ventricular Remodeling
Vascular Disease Prevention (Discontinued) Antibody Treatments of Inflammatory Arthritis
Current Medicinal Chemistry Antiangiogenic Therapies in Non-Hodgkin's Lymphoma
Current Cancer Drug Targets Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology Electrically-Assisted Nucleic Acids Delivery to Tissues In Vivo: Where Do We Stand?
Current Pharmaceutical Design Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Development and Tailoring of Hybrid Lipid Nanocarriers
Current Pharmaceutical Design Current Developments in the Analysis of Proteomic Data: Artificial Neural Network Data Mining Techniques for the Identification of Proteomic Biomarkers Related to Breast Cancer
Current Proteomics Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry Bio-inspired Biomaterials and their Drug Delivery Perspectives - A Review
Current Drug Metabolism In Vitro and In Vivo Investigations into the Carbene Copper Bromide Anticancer Drug Candidate WBC4
Letters in Drug Design & Discovery Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Tissue Transglutaminase Expression During Neural Differentiation of Human Mesenchymal Stem Cells
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: New Insight into Lipid Disorders)
Current Medicinal Chemistry Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Recent Development in [1,4]Benzodiazepines as Potent Anticancer Agents: A Review
Mini-Reviews in Medicinal Chemistry MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Current Pharmaceutical Design